Sanofi

Sanofi reports 15.7% Q3 sales growth, driven by vaccine sales and strong business performance, raising 2024 EPS guidance. Dupixent sales up 23.8%, with full-year target confirmed at €13 billion. Pharma launches grew 67.1%, led by ALTUVIIIO, Nexviazyme, and Rezurock. Vaccines sales increased 25.5%, boosted by flu sales and Beyfortus. Opella sales rose 7.9%, supported by Qunol acquisition. R&D expenses grew 12.7%, while SG&A expenses grew 6.4%. Business EPS at €2.86, up 12.2% reported and 17.6% at CER. Four regulatory approvals and four positive phase 3 data readouts achieved. Negotiations underway to transfer a controlling stake of Opella to CD&R. 2024 business EPS guidance upgraded to low single-digit growth at CER.

Regeneron and Sanofi presented Phase 3 LIBERTY-CUPID Study C data on Dupixent's efficacy in uncontrolled chronic spontaneous urticaria patients receiving antihistamines, showing significant itch and urticaria activity score reductions and higher well-controlled disease status rates compared to placebo. The data was presented at the ACAAI 2024 Annual Scientific Meeting. Dupixent's safety profile was consistent with its dermatological indications, with similar treatment emergent adverse event rates for Dupixent and placebo. Dupixent is approved for CSU in Japan and UAE, under review in EU, but not fully evaluated elsewhere.

Sanofi's Elizabeth Laws leads development of oral TNFR1 inhibitor SAR441566 for RA and psoriasis, aiming to offer safer, more effective alternatives to existing biologics.

Meharry Medical College received $18 million from Sanofi to boost diversity in clinical trials, partnering with Howard University and Morehouse School of Medicine over 10 years. The funds will support hiring, infrastructure, and training to ensure trials are inclusive and representative of all communities, aiming to close health disparities.

Motivated by improving lives and protecting public health, efforts focus on medicines and vaccines for difficult-to-treat diseases. The R&D pipeline includes 78 clinical-stage projects, with 32 in phase 3 or submitted for approval, supported by clinical trial volunteers.

The global Rx-to-OTC switches market is projected to reach USD 66.5 billion by 2033, driven by consumer convenience, cost-effectiveness, and regulatory support.

Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. The Phase 3 LIBERTY-CUPID Study C results support a U.S. regulatory resubmission by year-end, potentially making Dupixent the first new targeted treatment for CSU in over 10 years.

Dupixent significantly reduced itch and hive activity in chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive phase 3 data will be presented at ACAAI, supporting potential US regulatory resubmission by year-end, aiming for Dupixent to become the first new targeted treatment for CSU in over 10 years.

Regeneron and Sanofi present positive Phase 3 LIBERTY-CUPID Study C data on Dupixent in biologic-naïve CSU patients, showing significant itch and urticaria activity reduction and higher disease control rates compared to placebo, presented at ACAAI 2024.

Dupixent significantly reduced itch and hive activity in chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive phase 3 data to be presented at ACAAI 2024, supporting potential US regulatory resubmission by year-end, aiming for Dupixent to become the first new targeted treatment for CSU in over 10 years.